Anlotinib Plus Penpulimab (AK105) for Chemo-refractory Metastatic Colorectal Cancer:ALTER-C003

Colorectal Cancer Clinical Trial

— ALTER-C003  

Official title:

Anlotinib Hydrochloride In Combination With Penpulimab (AK105) in Patients With Chemo-refractory Metastatic Colorectal Cancer, Open, Single Arm,Exploratory Clinical Trial(ALTER-C003)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04970914
• Other study ID #: HS-2986B
• Status: Recruiting
• Phase: Phase 2
• Start date: November 5, 2021
• Est. completion date: August 23, 2023

Study information

• Verified date: March 2022
• Source: Peking Union Medical College Hospital
• Contact: Jianfeng Zhou
• Phone: 011-86-10-69156114
• Email: ZhouJF[@]pumch.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A single-arm, open-label clinical trial, focus on the safety and efficacy of anlotinib hydrochloride in combination with Penpulimab (AK105) in patients with Chemo-refractory Metastatic Colorectal Cancer (mCRC)

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 32
• Est. completion date: August 23, 2023
• Est. primary completion date: August 23, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients participate in the study voluntarily and sign informed consent with good compliance.

• Be 18 years of age or older on day of signing informed consent.

• Histological or cytological confirmation of Metastatic Colorectal Cancer(T1-4N0-2M1).

• At least one measurable lesion, with diameter = 10mm measured by spiral MRI/CT scan per RECIST1.1.

• Participants must have received and progressed through or become intolerant to fluoropyrimidine, irinotecan, oxaliplatin, Exceptions may apply.

• Eastern Cooperative Oncology Group Performance Status 0 or 1.

• Life expectancy of at least 3 months.

• Main organs function is normal. (normal main organs function as defined below:

Hemoglobin (Hb) = 90 g/L, Neutrophils (ANC) = 1.5×109/L, leucocyte (WBC) = 3.0×109/L,Platelet count (PLT) = 75×109/L,Total bilirubin (TBIL) = 1.5 × normal upper limit (ULN), Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) = 2.5 ×ULN, If liver metastasis is present,ALT and AST<5ULN ;Serum creatinine (Cr) = 1.5× ULN or Creatinine Clearance rate(CCr) =60ml/min,Doppler ultrasound evaluation: left ventricular ejection fraction (LVEF) > 50%)

• The woman patients of childbearing age who must agree to take contraceptive methods (e.g. intrauterine device, contraceptive pill or condom) during the research and within another 3 months after it; who are not in the lactation period and examined as negative in blood serum test or urine pregnancy test within 7 days before the research; The man patients who must agree to take contraceptive methods during the research and within another 8 weeks after it.

Exclusion Criteria:

• Histological or cytological confirmation of mucinous adenocarcinoma or ovarian transcoelomic metastasis

• Patients who had previously received treatment with Anlotinib or anti-programmed cell death protein 1 (PD-1), programmed cell death protein 1 ligand 1 (PD-L1), or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors other immunotherapy against .

• Patients who had previously received treatment within 2 weeks or Participated in other anti-tumor clinical trials within 4 weeks.

• Patients with a large amount of pleural effusion or ascites requiring drainage.

• Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.

• Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy.

• Patients who underwent major surgery within 4 weeks.

• Regardless of the severity, patients with any physical signs or history of bleeding, patients with bleeding or bleeding events greater than or equal to CTCAE 3 within four weeks prior to the first administration, or patients with unhealed wounds, fractures, ulcers.

• Patients with a risk of gastrointestinal bleeding may not be enrolled.

• Patients with arterial or venous thromboembolic events occurred within 6 months, such as cerebrovascular accident (including transient ischemic attack), deep vein thrombosis and pulmonary embolism.

• Patients with any severe and/or unable to control diseases,including: Patients with unsatisfactory blood pressure control using antihypertensive drugs (systolic blood pressure =150 mmHg or diastolic blood pressure =100) mmHg); Patients with Grade 2 or higher myocardial ischemia, myocardial infarction or malignant arrhythmias(including male QTc=450ms; female QTc=470ms) and patients with Grade 2 or higher congestive heart failure (NYHA Classification); Patients with active or unable to control serious infections, which is over level 2 in CTC AE (4.0); Patients with poorly controlled diabetes (fasting blood glucose(FBG)>10mmol/L); Patients with kidney failure who require hemodialysis or peritoneal dialysis; Patients with interstitial lung disease with symptoms or signs of activity;Patients with a history of immunodeficiency, including a positive HIV test or other acquired, congenital immunodeficiency disease, or a history of organ transplantation; Urine routine indicates that urine protein = ++, and confirmed 24-hour urine protein quantitation > 1.0 g; Patients with any of the following coagulation functions are abnormal, including: Prothrombin time (PT)>ULN+4s, Activated partial thromboplastin time (APTT) >1.5ULN s, international normalized ratio (INR)>1.5; Patients with a seizure disorder who require pharmacotherapy.

• Patients who have got non remissive toxic reactions derived from any treatment, which is over level 1 in CTC AE (4.0).

• Has a diagnosis of immunodeficiency or is receiving chronic steroid therapy of prednisone = 10 mg daily or any equivalent dose of corticosteroids.

• Has received a live vaccine or attenuated vaccine within 30 days prior to trial registration.

• Symptoms that affect oral medication and cannot be controlled through proper treatment (such as inability to swallow, chronic diarrhoea and intestinal obstruction, etc.).

• Female patients who are pregnant or breastfeeding.

• Patients with drug abuse history and unable to get rid of or patients with mental disorders.

• Patients who had serious adverse effect to Anlotinib or Penpulimab or any of its excipients

• Known hypersensitivity to other Monoclonal Antibody or any of its excipients.

• Patients with concomitant diseases which could seriously endanger their own safety or could affect completion of the study according to investigators' judgment.

Related Conditions & MeSH terms

• Colorectal Cancer
• Colorectal Neoplasms

Intervention

Drug:
• Anlotinib
12mg, continuous oral 2 weeks stop for 1 week, 21 days for a treatment cycle.
• Penpulimab
Penpulimab 200 mg administered intravenously every 3 weeks.

Locations

Country	Name	City	State
China	Beijing Tiantan Hospital, Capital Medical University	Beijing	Beijing
China	China-Japan friendship hospital	Beijing	Beijing
China	Peking Union Medical College Hospital	Beijing
China	Hebei Petro China Central Hospital	Langfang	Hebei
China	The First Hospital Of China Medical University	Shenyang
China	The People's Hospital Of Liaoning Province	Shenyang
China	The Fourth Hospital of Hebei Medical University (Hebei Cancer Hospital)	Shijiazhuang	Hebei
China	General Hospital of Tianjin Medical University	Tianjin	Tianjin

Sponsors (1)

Lead Sponsor	Collaborator
Peking Union Medical College Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Number of TB cells count and interleukin-6/8/10	Objectives to analyse the subsets of TB cells and interleukin-6/8/10 associated treatment.	through study completion, an average of 2 year
Primary	Progression-free survival (PFS)	Progression-free Survival (PFS) (median) was determined using the number of months measured from the initial date of treatment to the date of documented progression, or the date of death (in the absence of progression) of participants. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.	up to 24 months
Secondary	Objective Response Rate (ORR)	Objective response rate is defined as the percentage of subjects whose best response was complete response (CR) or partial response (PR) according to the RECIST v1.1	up to 24 months
Secondary	Disease Control Rate (DCR)	Disease control rate is defined as the percentage of subjects whose best response was CR, PR or stable disease (SD) according to the RECIST v1.1.	up to 24 months
Secondary	Duration of Response (DOR)	Duration of Response is defined as the percentage of subjects whose best response was CR, PR or stable disease (SD) according to the RECIST v1.1 or death due to any cause, whichever occurs first.	up to 24 months
Secondary	Number of participants with treatment-related adverse events as assessed by CTCAE v5.0	Adverse events assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (version 5.0).	Until 30 day safety follow-up visit
Secondary	Overall Survival (OS)	Overall Survival (OS) (median) is determined using the number of months measured from the initial date of treatment to the recorded date of death of participants.	Up to 24 months